NewAmsterdam Pharma (NAMS) Earnings Date, Estimates & Call Transcripts $21.84 +1.68 (+8.33%) Closing price 04:00 PM EasternExtended Trading$21.79 -0.05 (-0.23%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NewAmsterdam Pharma Earnings Summary NewAmsterdam Pharma posted Q1 2025 earnings on May 8, 2025, reporting an EPS of -$0.49, which missed the consensus estimate of -$0.45 by $0.04. Quarterly revenue was reported to be $2.98 million, above analyst estimates of $1.46 million. With a trailing EPS of -$1.88, NewAmsterdam Pharma's earnings are expected to decrease next year, from ($1.75) to ($1.79) per share. Upcoming Q2 Earnings DateAug. 6Before Market OpensEstimatedConsensus EPS (May. 8) -$0.45 Actual EPS (May. 8) -$0.49 Missed By -$0.04 Actual Revenue (May. 8) $2.98MQ1 2025 Earnings ResourcesQ1 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)NAMS Upcoming EarningsNewAmsterdam Pharma's next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Powered by Get NewAmsterdam Pharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNAMS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NAMS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. NewAmsterdam Pharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.51-$0.20-$0.39Q2 20253-$0.52-$0.34-$0.43Q3 20253-$0.54-$0.35-$0.46Q4 20253-$0.55-$0.35-$0.47 FY 2025 12 -$2.12 -$1.24 -$1.75 Q1 20261-$0.54-$0.54-$0.54Q2 20261-$0.53-$0.53-$0.53Q3 20261-$0.54-$0.54-$0.54Q4 20261-$0.56-$0.56-$0.56 NewAmsterdam Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/8/2025Q1 2025-$0.45-$0.49 -$0.04-$0.34$1.46M$2.98M2/26/2025Q4 2024-$0.48-$0.95 -$0.47-$0.95$3.30M$12.77M8/7/2024Q2 2024-$0.59-$0.51+$0.08-$0.61$2.20M$2.28M5/8/2024Q1 2024-$0.54-$0.62 -$0.08-$0.18$2.95M$1.40M NewAmsterdam Pharma Earnings - Frequently Asked Questions When is NewAmsterdam Pharma's earnings date? NewAmsterdam Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on NAMS's earnings history. Did NewAmsterdam Pharma beat their earnings estimates last quarter? In the previous quarter, NewAmsterdam Pharma (NASDAQ:NAMS) missed the analysts' consensus estimate of ($0.45) by $0.04 with a reported earnings per share (EPS) of ($0.49). Learn more on analysts' earnings estimate vs. NAMS's actual earnings. How much revenue does NewAmsterdam Pharma generate each year? NewAmsterdam Pharma (NASDAQ:NAMS) has a recorded annual revenue of $47.14 million. How much profit does NewAmsterdam Pharma generate each year? NewAmsterdam Pharma (NASDAQ:NAMS) has a recorded net income of -$176.94 million. NAMS has generated -$1.88 earnings per share over the last four quarters. What is NewAmsterdam Pharma's EPS forecast for next year? NewAmsterdam Pharma's earnings are expected to decrease from ($1.75) per share to ($1.79) per share in the next year. More Earnings Resources from MarketBeat Related Companies BPMC Earnings ROIV Earnings RVMD Earnings VRNA Earnings BBIO Earnings ELAN Earnings GRFS Earnings TGTX Earnings NUVL Earnings LEGN Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal This page (NASDAQ:NAMS) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
